ImmunoGen Inc. (NASDAQ:IMGN) was down 3.4% during trading on Monday . The company traded as low as $3.07 and last traded at $3.09, with a volume of 846,705 shares traded. The stock had previously closed at $3.20.

A number of equities research analysts have recently commented on IMGN shares. Canaccord Genuity reaffirmed a “buy” rating on shares of ImmunoGen in a research report on Saturday, April 30th. Cantor Fitzgerald reissued a “hold” rating on shares of ImmunoGen in a research report on Wednesday, June 8th. Zacks Investment Research lowered ImmunoGen from a “hold” rating to a “sell” rating in a research report on Monday, July 4th. Cowen and Company reissued a “hold” rating on shares of ImmunoGen in a research report on Monday, June 6th. Finally, Leerink Swann lifted their target price on ImmunoGen from $8.00 to $11.00 and gave the company a “market perform” rating in a research report on Monday, May 2nd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $12.59.

The company has a 50-day moving average of $4.33 and a 200 day moving average of $7.51. The firm’s market capitalization is $257.74 million.

ImmunoGen (NASDAQ:IMGN) last announced its earnings results on Friday, April 29th. The biotechnology company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.06. The company earned $19.71 million during the quarter, compared to the consensus estimate of $23.02 million. During the same quarter last year, the firm posted ($0.25) EPS. ImmunoGen’s quarterly revenue was up 72.4% compared to the same quarter last year. Analysts anticipate that ImmunoGen Inc. will post ($1.54) earnings per share for the current fiscal year.

Other large investors have made changes to their positions in the company. Oxford Asset Management acquired a new stake in shares of ImmunoGen during the fourth quarter valued at approximately $2,359,000. ProShare Advisors LLC raised its stake in shares of ImmunoGen by 10.7% in the fourth quarter. ProShare Advisors LLC now owns 82,498 shares of the biotechnology company’s stock valued at $1,120,000 after buying an additional 7,949 shares during the last quarter. Pinnacle Associates Ltd. raised its stake in shares of ImmunoGen by 44.6% in the fourth quarter. Pinnacle Associates Ltd. now owns 1,768,359 shares of the biotechnology company’s stock valued at $23,997,000 after buying an additional 545,784 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of ImmunoGen by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 159,672 shares of the biotechnology company’s stock valued at $2,167,000 after buying an additional 2,537 shares during the last quarter. Finally, Cornerstone Capital Management Holdings LLC. raised its stake in shares of ImmunoGen by 91.3% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 227,703 shares of the biotechnology company’s stock valued at $3,090,000 after buying an additional 108,703 shares during the last quarter.

ImmunoGen, Inc (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Company’s clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.